Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
ACTIVE NOT RECRUITING
NCT05450705
PHASE3

V503 in Chinese Girls 9-14 Years Old Versus Chinese Women 20-26 Years Old (V503-071)

Sponsor: Merck Sharp & Dohme LLC

View on ClinicalTrials.gov

Summary

This study aims to demonstrate that a 2-dose regimen of the 9-Valent Human Papillomavirus (9vHPV) vaccine (GARDASIL™9, V503) induces non-inferior competitive Luminex immunoassay (cLIA) geometric mean titers (GMTs) to each of the 9vHPV vaccine types in Chinese girls 9 through 14 years of age compared to a 3-dose regimen in Chinese women 20 through 26 years of age. The primary hypothesis is that a 2-dose regimen has a non-inferiority margin of 0.67 in the GMT ratio (girls vs. women) for each HPV type.

Official title: A Phase 3 Open-Label Immunogenicity and Safety Study of 2-Dose Regimens of a 9vHPV Vaccine (V503) in Chinese Girls 9 Through 14 Years of Age With a Comparison to 3-Dose Regimen of V503 in Chinese Women 20 Through 26 Years of Age

Key Details

Gender

FEMALE

Age Range

9 Years - 26 Years

Study Type

INTERVENTIONAL

Enrollment

1500

Start Date

2022-07-22

Completion Date

2029-08-03

Last Updated

2022-09-02

Healthy Volunteers

Yes

Interventions

BIOLOGICAL

9vHPV vaccine

A 9-valent HPV vaccine (Types 6, 11, 16, 18, 31, 33, 45, 52, and 58) will be administered as a 0.5 mL IM injection.

Locations (2)

Jiangshan Center for Disease Control and Prevention ( Site 0001)

Quzhou, Zhejiang, China

Yuhuan Center for Disease Control and Prevention ( Site 0002)

Taizhou, Zhejiang, China